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Abstract 
OBJECTIVES The “portal hypothesis” proposes that the liver is directly exposed to free fatty 
acids and cytokines increasingly released from visceral fat tissue into the portal vein of obese 
subjects, thus rendering visceral fat accumulation particularly hazardous for the development 
of hepatic insulin resistance and type 2 diabetes. In the present study we utilized a fat 
transplantation paradigm to (artificially) increase intra-abdominal fat mass in order to test the 
hypothesis that venous drainage of fat tissue determines its impact on glucose homeostasis. 
RESEARCH DESIGN AND METHODS Epididymal fat pads of C57Bl6/J donor mice were 
transplanted into littermates, either to the parietal peritoneum (caval/systemic venous 
drainage) or, by utilizing a novel approach, to the mesenterium, which confers portal venous 
drainage.  
RESULTS Only mice receiving the portal drained fat transplant developed impaired glucose 
tolerance and hepatic insulin resistance. mRNA expression of pro-inflammatory cytokines 
was increased in both, portally and systemically transplanted fat pads. However, portal vein 
(but not systemic) plasma levels of IL-6 were elevated only in mice receiving a portal fat 
transplant. Intriguingly, mice receiving portal drained transplants from IL-6 knockout mice 
showed normal glucose tolerance.  
CONCLUSIONS These results demonstrate that the metabolic fate of intra-abdominal fat 
tissue transplantation is determined by the delivery of inflammatory cytokines to the liver 
specifically via the portal system providing direct evidence in support of the portal 
hypothesis.  
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Introduction 
Several hypotheses have been formulated and pursued to explain the deteriorating 
impact of intra-abdominal (visceral) adipose tissue accumulation on glucose metabolism: 
intra-abdominal fat tissue may be inherently different from subcutaneous fat, e.g. in cellular 
composition, tissue dynamics (tendency to respond to excess calories with a hypertrophic 
rather than a hyperplastic response), adipokine release and hormonal responses. Alternatively 
(or complementarily), the venous drainage of subcutaneous fat differs from that of visceral 
fat: secreted products such as adipocytokines and FFAs from subcutaneous fat are drained 
systemically into the vena cava, whereas secreted product from mesenteric or visceral fat are 
drained into the portal system. Exaggerated hepatic delivery of FFAs and pro-inflammatory 
cytokines originating from adipose tissue (and/or the gastrointestinal tract) result in hepatic 
insulin resistance and metabolic deterioration constituting "the portal theory" (1-4). 
We previously found that increasing fat mass by intra-abdominal transplantation of fat 
pads isolated from healthy, non-insulin resistant littermates could not recapitulate the effects 
of fat accumulation in obesity in healthy recipient mice. Instead, increased insulin sensitivity 
and improved glucose tolerance were observed (5). Yet, blood from these fat pads is drained 
into the vena cava inferior and, thus, reaches the systemic circulation while circumventing the 
liver. A prominent hypothesis linking visceral/intra-abdominal adiposity to cardio-metabolic 
diseases involves the tight association with fatty liver diseases, which is explained by the 
portal theory. Thus, it is plausible that the metabolic effect of intra-abdominal adipose tissue 
transplantation depends on the venous drainage of the transplant. Indeed, in a very recent 
study no difference was reported in glucose tolerance between mice receiving an intra-
abdominal fat transplant and sham-operated mice (6), potentially because transplants were 
drained to both the caval as well as the portal circulation.  
The aim of the present study was to test the hypothesis that venous drainage of fat tissue 
determines its impact on glucose homeostasis. To this end, we developed a novel approach to 
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mimic visceral fat accumulation by transplanting fat pads from a donor mouse to the 
mesenterium of a recipient littermate. These pads are drained solely to the portal vein. In 
contrast to mice receiving caval drained fat pad transplantation, mice receiving a portal 
drained fat pad developed (hepatic) insulin resistance and were glucose intolerant. 
Furthermore, we present evidence that IL-6 is at least partly responsible for impaired glucose 
metabolism in these mice. Thus, our results hint towards an important influence of venous 
drainage of fat pads on glucose homeostasis, supporting the portal hypothesis.  
 
 
Research Design and Methods 
 
Animals. Male C57BL6JOlaHsd mice were purchased from Harlan Netherlands (Horst, The 
Netherlands), male IL-6 KO mice and respective wild-type mice were from Charles River 
Laboratories (Wilmington, MA, USA). All mice were housed in a pathogen-free environment 
on a 12-h light-dark cycle, with free access to standard rodent diet (Provimi Kliba, 
Kaiseraugst, Switzerland). All protocols conformed to the Swiss animal protection laws and 
were approved by the Cantonal Veterinary Office in Zurich, Switzerland. 
 
Surgical procedure. Transplantation procedure was performed at 6 weeks of age. Mice were 
anaesthetized with isoflurane (Abbott, Baar, Switzerland). Both epididymal fat pads (average 
size per pad 75 mg [range: 65-90 mg]) were removed from the donor mouse, rinsed with 0.9% 
saline and thereafter stitched to the visceral side of the peritoneum (caval transplantation) or 
to the mesenterium of the recipient mouse (portal transplantation) using Monocryl 6.0 
(Johnson-Johnson, Spreitenbach, Switzerland). Sham-operated control mice received the 
same treatment, but instead of the fat pad transplantation, an artificial suture was performed 
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with Monocryl. Subcutaneous injection of buprenorphine every 12 h for 2 days was used for 
analgesia. In order to prevent transplant rejection, donor and recipient mice were littermates. 
 
Glucose tolerance tests. For the intraperitoneal glucose tolerance test (ipGTT) mice were 
fasted overnight.  Glucose (2g/kg body weight) was injected intraperitoneally and blood was 
collected from the tail vein at different time points, as indicated (5). Plasma glucose was 
measured using a glucose meter (Ascensia Contour; Bayer, Zurich, Switzerland). 
 
Histology. Epididymidal fat tissues were fixed in 4% buffered formalin and imbedded in 
paraffin. Sections were obtained either at the time of sacrifice and stained with 
Hematoxylin/Eosin. For each fat pad of a mouse at least 100 adipocytes were analyzed. 
Images were analyzed using ImageJ software for quantification (National Institutes of Health, 
Bethesda, MD). Macrophages were immunostained with mac2 antibody. Mac2 positive cells 
were counted per nuclei of seven randomly selected fields per section containing at least 90 
cells. 
 
Hyperinsulinemic-euglycemic clamps. Clamps were performed in freely moving mice 5 
weeks after transplantation as described previously (7). Glucose infusion rate (GIR) was 
calculated once glucose infusion reached a more or less constant rate with blood glucose 
levels at 5 mM. This was reached in most mice 80-90 minutes after the start of insulin 
infusion. Thereafter, blood glucose was kept constant at 5 mM for 20 minutes (with no or 
minimal adjustment of the glucose infusion rate) and GIR was calculated. The glucose 
disposal rate (GDR) was calculated by dividing the rate of 3-[3H]-glucose infusion by the 
plasma 3-[3H]-glucose specific activity (8; 9). Endogenous glucose production (EGP) during 
the clamp was calculated by subtracting the glucose infusion rate from the glucose disposal 
rate (8; 9). Insulin-stimulated glucose disposal rate (IS-GDR) was calculated by subtracting 
 6
basal endogenous glucose production (equal to basal glucose disposal rate) from glucose 
disposal rate during the clamp (10). 
 
Determination of plasma adiponectin, leptin, IL-6, insulin, and FFA. Plasma adiponectin, 
leptin and IL-6 levels were determined with mouse LINCOplex kits from Linco Research, 
Inc. (Labodia, Yens, Switzerland), plasma insulin and FFA levels were measured as 
previously described (5). 
 
Total liver lipid extraction. Liver tissue (30mg) was homogenized in PBS and lipids were 
extracted in a chloroform-methanol (2:1) mixture. Total liver lipids were determined by a 
sulfophosphovanillin reaction as previously described (7). 
 
RNA extraction and quantitative reverse transcription-PCR (RT-PCR). Total RNA from fat 
pads was extracted with the RNeasy lipid tissue mini kit (Qiagen). 0.75 μg of RNA was 
reverse transcribed with Superscript III Reverse Transcriptase (Invitrogen) using random 
hexamer primer (Invitrogen). Taqman system (Applied Biosystems) was used for real-time 
PCR amplification. Relative gene expression was obtained after normalization to 18sRNA 
(Applied Biosystems), using the formula 2-ΔΔcp (11). The following primers were used: TNF-α 
Mm004483258_m1, IL-6 Mm00446190_m1, KC Mm00433859_m1, IL-1β 
Mm0043422/_m1, MCP-1 Mm00441242_m1, Fas Mm00433237_m1, FasL 
Mm00438864_m1, cd11c Mm00498698_m1, Hif-1α Mm00468869_m1, SOCS.3 Mm 
00545913_s1, CD68 Mm03047343_m1, F4/80 Mm00802529_m1, cd11b Mm00434455_m1 
(Applied Biosystems).   
 
Western Blot. Western blotting was performed as previously described (7). The following 
antibodies were used: anti-phospho-Akt (S473) and anti-Akt were purchased from Cell 
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Signaling, secondary horseradish peroxidase-conjugated antibody from either Santa Cruz 
Biotechnology or Alexis Biochemicals. 
 
Data analysis. Data are presented as means +/- SEM and were analyzed by Student’s t test or 
ANOVA with a Turkey correction for multiple group comparisons. 
 
 
Results 
To estimate potential metabolic effects of an artificial increase in fat tissue mass drained 
uniquely into the portal system, epididymal fat pads of a regular chow-fed donor mouse were 
transplanted to the mesenterium of a chow-fed littermate mouse using a novel surgical 
approach. At the time of sacrifice (five weeks after transplantation), transplanted fat pads 
were adherent to the mesenterium and well vascularised (Fig. 1A). Sham operation was 
performed in control littermates. Mice tolerated the surgical procedure and the fat 
transplantation well - no adverse events were noted. In order to confirm venous drainage of 
transplanted fat pads to the portal vein, Evans Blue was injected retrogradely into the portal 
vein. As depicted in Fig. 1B, transplanted fat pads were stained with Evans Blue as was 
endogenous mesenteric fat tissue, but not the caval-drained epididymal fat tissue, confirming 
the portal drainage of the mesenteric-transplanted fat tissue.  
We have previously shown that mice receiving fat pads drained to the inferior  vena 
cava (caval-drained fat transplant; cTx) had improved glucose tolerance (5). Four weeks after 
transplantation, body weight gain was not different between sham-operated mice and mice 
receiving a portal drained fat transplant (3.0±0.4 g vs. 2.9±0.5 g; p=0.85). However, as 
depicted in Fig. 1C, increase in blood glucose concentrations after an intraperitoneal glucose 
load was significantly higher in mice receiving a fat transplant drained to the portal vein 
(portal drained fat pad transplantation; pTx) compared to mice receiving caval drained fat pad 
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transplantation (cTx) as well as to sham-operated mice, indicating impaired glucose tolerance 
in mice receiving a portal drained fat pad transplant. 
To determine whether the effect on glucose homeostasis of one transplantation site 
predominates over the other, a double transplantation approach was performed, i.e. one 
epididymal fat pad of the donor mouse was stitched to the peritoneum (and, thus, drained to 
the inferior caval vein), the other pad was stitched to the mesenterium (and, thus, drained to 
portal vein). Transplanted fat pads were similar in size and originated from the same donor 
mouse, which was a littermate of the recipient mouse. As depicted in Fig. 1D glucose 
tolerance in such transplanted mice was not different form sham-operated mice four weeks 
after surgery.  
We next assessed adipose tissue morphology of endogenous and transplanted fat pads in 
sham-operated and portal transplanted (pTx) mice (Fig. 2A). As depicted in Fig. 2B, 
perimeters of endogenous epididymal and mesenteric adipocytes were similar in both groups. 
However, epididymal adipocytes were larger compared to mesenteric adipocytes. Moreover, 
adipocytes in portal transplanted fat pads were similar in size as endogenous mesenteric 
adipocytes but smaller compared to endogenous epididymal adipocytes. Furthermore, 
macrophage infiltration rate was much higher in portal transplanted compared to endogenous 
epididymal fat pads of transplanted and sham-operated mice (Fig. 2C).  
Consistent with the portal theory, we hypothesized that portal-drainage of fat transplant 
would cause hepatic insulin resistance, and to assess this possibility a hyperinsulinemic-
euglycemic clamp was performed five weeks after surgery. Glucose infusion rate was 
significantly lower in portal transplanted mice compared to sham-operated mice (Fig. 3A and 
Fig. S1). Moreover, during hyperinsulinemic-euglycemic clamp, insulin-induced suppression 
of endogenous glucose production was blunted in mice receiving a fat pad transplant drained 
to the portal vein, but was clearly evident in sham-operated mice (Fig. 3B, left panel). 
Therefore, mice receiving portal drained fat pad transplants developed hepatic insulin 
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resistance. Furthermore, insulin-induced phosphorylation of Akt was markedly reduced in 
livers of portal transplanted mice compared to that of sham-operated mice (Fig. 3C, left 
panel). This eminent reduction in hepatic insulin signaling confirmed the development of 
hepatic insulin resistance in portal transplanted mice. In contrast, glucose disposal rate (Fig. 
3B, right panel) as well as insulin signaling in skeletal muscle were not affected by the portal-
drained transplant (Fig. 3C, right panel), suggesting maintained insulin-sensitivity of skeletal 
muscle. Intriguingly, insulin levels (four hours after food withdrawal) were only slightly 
increased in systemic but clearly elevated in portal blood samples of mice receiving a portal 
fat transplantation compared to sham-operated mice (Fig. 3D) matching the clamp results 
presented above. Further metabolic characteristics of sham-operated and portal transplanted 
mice are presented in Tab. 1. 
The development of hepatic insulin resistance is often associated with hepatic steatosis 
and Kupffer cell activation (12). Thus, hepatic lipid contents as well as expression levels of 
tissue macrophage markers were assessed. Histological examinations and biochemical 
determination of total hepatic lipid content was similar in sham-operated and peritoneal 
transplanted mice (Fig. 4A). Moreover, no increased infiltration/activation of hepatic Kupffer 
cells was detected (Fig. 4B). Consistent with the absence of hepatic steatosis in portal 
transplanted mice, no differences in systemic and portal plasma free fatty acids (FFA) levels 
were found in both groups of mice (Fig. 4C). Similarly, no difference in circulating 
adiponectin and leptin levels occurred (Tab. 1.). Thus, transplantation of fat pads to sites 
drained by the portal vein induces hepatic insulin resistance independently of hepatic steatosis 
and Kupffer cell infiltration/activation.  
We next sought to investigate potential mediators of hepatic insulin resistance observed 
in mice receiving portal-drained transplant. Transplanted fat tissue may not acquire the exact 
biological function as the endogenous fat tissue of the same depot, and its function may be 
affected by a combination of host and donor factors. Thus, to determine potential differences 
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between caval and portal transplanted fat pads, we utilized endogenous and transplanted fat 
depots from the double transplanted mice. Such approach allowed us to exclude different host 
factors, as well as secondary metabolic effects induced by cTx versus pTx, as shown in Fig. 1. 
As depicted in Fig. 5A, transplanted fat tissue of either localization exhibited a much more 
inflammatory gene expression profile than endogenous epididymal fat pads, as assessed by 
mRNA expression of pro-inflammatory cytokines and cd11c. Yet intriguingly, when 
comparing portal transplanted to caval transplanted fat pads, the former exhibited higher 
expression levels of IL-6 and Fas ligand (FasL).  
Since IL-6 was previously associated with hepatic insulin resistance (7; 13) we 
postulated that increased IL-6 expression and secretion from portal transplanted fat pads 
might be responsible for hepatic insulin resistance. Thus, IL6 was determined in systemic and 
portal vein plasma samples of sham-operated and portal transplanted mice. Systemic and 
portal IL-6 plasma levels were similar in sham-operated mice, whereas IL-6 concentration 
was more than 70% higher in portal compared to systemic blood samples of mice receiving a 
portal drained fat transplant (Fig. 5B). Even though this difference was not significant these 
data suggest increased delivery of IL-6 to the liver of mice receiving a portal transplant, 
potentially originating from the transplanted fat pad. Consistent with an increased delivery of 
IL-6 to the liver, hepatic SOCS3 mRNA expression, which is induced by IL-6 (14; 15), was 
enhanced in mice receiving a portal transplanted fat pad (Fig. 5C).  
To substantiate the potential contribution of IL-6 to the induction of insulin resistance in 
portal transplanted mice, epididymal fat pads of an IL-6 knockout donor were transplanted 
into a wildtype recipient (pTx-IL6KO). Characteristics of these mice are given in Tab. S1. As 
shown in Fig. 6A, glucose tolerance of such transplanted mice was not impaired compared to 
sham-operated wildtype mice. Moreover, the insulin-induced increase in Akt-phosphorylation 
in liver samples was completely maintained in these mice (Fig. 6B) in contrast to mice 
receiving a portal drained transplant from wildtype mice (Fig. 3C). In addition, hepatic 
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SOCS-3 mRNA expression was not increased likely due to IL-6 deficiency (Fig. 6C). These 
results point towards a causative role for IL-6 in the development of insulin resistance in 
portal transplanted mice.  
 
 
Discussion 
The “portal hypothesis” proposes that the liver is directly exposed to free fatty acids and 
cytokines increasingly released from visceral fat tissue into the portal vein of obese subjects 
and, thus, rendering visceral fat accumulation particularly hazardous for the development of 
hepatic insulin resistance and type 2 diabetes (2; 3). In the present study we utilized a fat 
transplantation paradigm to (artificially) increase fat mass depot-specifically. In accordance 
with the portal hypothesis, we demonstrate that fat transplant localization through its venous 
drainage determines its effect on glucose homeostasis.  
When utilizing a fat pad transplantation paradigm, several factors need to be taken into 
account: i. the source of the transplanted tissue, i.e. which fat depot is utilized; ii. the 
functional outcome of the transplant may depend on a myriad of host and transplant factors, 
which include (but are not limited to) the location (and thus venous drainage) of the 
transplant. Previous studies by different groups including our own have examined the effect 
of adipose tissue transplantation into the abdominal cavity (5; 6; 16). Yet, whereas our group 
only used epididymal fat pads for transplantation, the other groups implemented both 
subcutaneous and epididymal fat pads (6; 16). In contrast to the study presented here, Tran et 
al. observed no changes in glucose tolerance when epididymal fat pads were transplanted into 
the abdominal cavity (6). However, as discussed by the authors, fat pads were drained both to 
the caval as well as to the portal vein. Similarly, we show here that such dual drainage of 
transplanted fat tissue may in fact result in no net alteration in glucose tolerance (Fig. 1D). 
One potential explanation might be the fact that the beneficial metabolic effect of the 
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systemically-drained fat transplant (5) was balanced by the detrimental effect of the portal-
drained transplant. On the other hand, the lack of deterioration in glucose homeostasis of 
double-transplanted mice or in the study by Tran et al. might be due to other reasons. 
We further utilized the pTx paradigm to determine potential mediators of hepatic insulin 
resistance in conditions with increased visceral adiposity. Adipose tissue inflammation was 
previously correlated with hepatic insulin resistance and IL-6 was suggested as a potential 
candidate (7; 13; 17). Indeed, IL-6 treatment of hepatocytes induced insulin resistance in vitro 
(18) and it seems to be generally accepted that IL-6 causes hepatic insulin resistance (19). 
Particularly, IL-6 was shown to activate the negative insulin signaling regulator SOCS3 in 
C57BL/6J mice (14; 15) resulting in reduced activation of phosphatidylinositol 3-kinase and 
Akt (18). Furthermore, IL-6 plasma concentration was 50% greater in the portal vein than in 
systemic circulation in obese subjects and portal vein IL-6 concentration correlated directly 
with systemic C-reactive protein concentrations (20). Accordingly, IL-6 expression in portal 
transplanted adipose tissue and IL-6 levels in the portal vein of such transplanted mice were 
increased (Fig. 5B), whereas portal IL-6 concentration was not increased in caval transplanted 
mice (Fig. S2). Moreover, hepatic SOCS3 expression was induced (Fig. 5C) and, consistently, 
insulin-stimulated Akt-phosphorylation was reduced in liver samples of mice receiving portal 
transplants (Fig. 3C). Both changes could be prevented in mice receiving transplants from IL-
6 knockout mice (Fig. 6B/6C). Interestingly, IL-6 mRNA expression was also significantly 
increased in caval transplanted fat pads compared to endogenous (epididymal) fat pads (Fig. 
5A), consistent with the transplanted fat depot being the source of the elevated portal IL-6 
levels.  
Remarkably, fat pads transplanted to both sites were characterized by increased 
expression of pro-inflammatory cytokines (Fig. 5A). Potential explanations might be a 
transplant rejection reaction (even though recipient and donor mouse were littermates of 
inbred colonies) or an inflammatory reaction due to transient transplant hypoxia. Intriguingly, 
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increased production of pro-inflammatory cytokines by the transplanted fat pads only 
deteriorated glucose metabolism when they were drained to the portal vein. Moreover, 
mesenteric transplantation of peritoneal tissue that did not contain adipose tissue had no effect 
on glucose tolerance (Fig. S3). These data suggest that the transplantation procedure on its 
own does not deteriorate glucose homeostasis, for example, by altering the delivery of 
inflammatory mediators from the GI-tract. Such finding emphasizes the importance of fat 
tissue localization and, thus, vascular drainage and suggests that the increased production of 
pro-inflammatory cytokines as it is found in obesity is particularly detrimental when released 
into the portal circulation supporting the portal hypothesis (3). However, it needs to be 
emphasized that we examined an artificial system herein, and, even though increased 
expression of pro-inflammatory cytokines in adipose tissue of obese subjects was previously 
demonstrated (21), the findings presented here may not be extrapolated to the situation of 
mesenteric fat accumulation and. Therefore, we presently cannot exclude that the impaired 
glucose tolerance observed in the portally transplanted mice may not be due to the additional 
adipose tissue per se but rather due to the increased inflammatory products related to the 
transplantation procedure.   
Moreover, besides IL-6 other factors may have contributed to the deterioration of 
glucose tolerance and hepatic insulin resistance. Interestingly, lack of IL-6 also reduced 
expression of other pro-inflammatory factors such as IL-1β in adipose tissue (Fig. S4). In 
addition, reduced cd11c expression levels point towards reduced macrophage infiltration. 
Rotter et al. suggested that IL-6 induce insulin resistance in concert with other cytokines that 
are also upregulated in adipocytes (22). Especially IL-6 and IL-1β were shown to mediate the 
change of hepatic glucose metabolism, influencing the glucoregulatory action of insulin 
through their signal pathways involving protein phosphorylation (21; 23). Interestingly, we 
found increased levels of FasL in portal transplanted fat pads. We previously reported that Fas 
activation by FasL-treatment induced secretion of IL-6 in 3T3-L1 adipocytes (7). Conversely, 
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adipocyte-specific Fas-knockout mice showed decreased IL-6 expression in adipose tissue 
and reduced circulating IL-6 levels (7). Thus, FasL-induced Fas-activation might be 
responsible for increased IL-6 secretion of portal transplanted fat pads ultimately inducing 
hepatic insulin resistance. In support of the latter, FasL expression was not reduced in portal 
transplanted IL-6 deficient fat pads suggesting that Fas-activation may be indeed upstream of 
IL-6 release (Fig. S4). 
Strikingly, hepatic insulin resistance in our model was not associated with hepatic 
steatosis (Fig. 4A) or increased hepatic Kupffer cell activation (Fig. 4B) as it is often 
observed in high fat diet-induced hepatic insulin resistance (12).  These changes might be due 
to a direct effect of high fat diet on liver metabolism or due to an increased release of FFAs 
from (mesenteric) adipose tissue. Consistent with the latter notion, FFA levels were found to 
be increased in high fat fed mice, which was not the case in our study.  
In conclusion, our results demonstrate that the metabolic fate of intra-abdominal fat 
tissue transplantation is determined by the delivery of inflammatory cytokines to the liver 
specifically via the portal system providing clear direct support for the portal hypothesis. 
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Figure Legends 
 
Fig. 1 
Transplantation was performed at 6 weeks of age. Both epididymal fat pads were removed 
from a donor mouse and stitched to the mesenterium (pTx) of a littermate recipient. (A) Six 
weeks after transplantation, the abdominal cavity was opened and the transplanted fat pad was 
visualized. (B) To confirm portal drainage of transplanted fat pads, Evans Blue dye (5mg/ml) 
was injected into the portal vein. Arrow: portal transplanted fat pad. (C) Intraperitoneal 
glucose tolerance test (2 g glucose/kg body weight) was performed four weeks after surgical 
procedure in mice receiving portal drained transplants (pTx; ?), in mice receiving caval 
drained transplants (cTx; ?) or in sham-operated mice (?) after a overnight fast. Results are 
expressed as mean blood glucose concentration (left panel) or area under curve (right panel) ± 
SEM of 5 (pTx), 16 (cTx) or 23 (Sham) animals. **p < 0.01, #p < 0.001 (ANOVA). (D) Both 
epididymal fat pads were removed from a donor mouse. One was stitched to the peritoneum 
(caval drained; cTx) and the other to the mesenterium (portal drained; pTx) of a littermate. 
Intraperitoneal glucose tolerance test (2 g glucose/kg body weight) was performed four weeks 
after surgical procedure in mice receiving a double transplant (cTx+pTx; Δ) or in sham-
operated mice (?) after a overnight fast. Results are expressed as mean blood glucose 
concentration ± SEM of 3-8 animals. 
 
Fig. 2 
(A) Representative, Hematoxylin- and Eosin-stained histological sections of endogenous 
epididymal, endogenous mesenteric or portal-transplanted fat pads from sham-operated and 
pTx mice are shown 5 weeks after surgery. Adipocyte cell perimeter was measured using 
ImageJ. (B) Up to 100 cells for each fat pad were analyzed and the results represent the mean 
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± SEM of three or four different mice. All values are expressed relative to the adipocyte cell 
perimeter of endogenous epididymidal fat pad of sham-operated mice. Black bar: sham-
operated mice; white bar: mice receiving a portal fat transplant. (C) Histological sections of 
endogenous epididymal and portal transplanted tissue were immunostained with mac2 
antibody. Mac2 positive cells were counted in seven randomly selected fields per section 
(about 90 cells) and expressed relative to total cell nucleus content. Results represent the 
mean ± SEM of three to five different mice.  
 
Fig. 3 
(A, B) Hyperinsulinemic-euglycemic clamps were performed 5 weeks after transplantation. 
(A) Mean glucose infusion rate 80-120 minutes after start of insulin infusion (see research 
design and methods). (B) Endogenous glucose production (EGP; left panel) as well as insulin-
stimulated glucose disposal rate (IS-GDR; right panel) were calculated in the basal period and 
in response to insulin infusion (18 mU/kg/min) during the clamp study. Results are the mean 
± SEM of 5-6 animals. *p < 0.05 (Student’s t test). (C) Insulin (1U/kg) was injected i.p. in 
overnight fasted mice 5 weeks after transplantation. Liver and skeletal muscle samples were 
harvested 15 minutes later and phosphorylation of Akt at S473 was determined by Western 
blotting. A representative blot is shown in the upper panel. Results are the mean ± SEM of 3-
4 animals. **p < 0.01 (Student’s t test). (D) Blood samples were obtained as indicated and 
insulin was determined as described in Methods. Results are expressed as mean plasma 
insulin concentration ± SEM of 5-6 animals. 
 
Fig. 4 
(A) Left panel: H&E stained liver sections from sham-operated and pTx mice. Right panel: 
total liver lipids were determined and expressed relative to liver weight. Results represent the 
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mean ± SEM of 4 to 6 mice of each group. (B) mRNA expression of indicated markers in 
liver tissue of sham-operated and pTx mice was analyzed. Results are the mean ± SEM of 5 
mice per group, expressed relative to WT and normalized to expression of 18S. (C) FFA 
levels were determined in systemic and portal plasma samples of mice receiving a portal 
drained fat transplant (pTx) and in sham operated mice after 3 hours of fasting. Results are the 
mean ± SEM of 5-6 animals.  
 
Fig. 5 
(A) Five weeks after transplantation endogenous epididymal fat pads (endo), the portal 
drained transplant (pTx) and the caval drained transplant (cTx) were collected and rtPCR was 
performed. Results are the mean ± SEM of 2-7 animals. ** p < 0.01 pTx vs. cTx (ANOVA). 
(B) IL-6 was measured in systemic and portal plasma samples of mice receiving a portal 
drained fat transplant (pTx) and in sham operated mice. Results are the mean of ± SEM of 8-
10 animals. (C) Five weeks after transplantation liver tissue was collected and rtPCR was 
performed. Results are the mean ± SEM of 4-5 animals.  
 
Fig. 6 
Both epididymal fat pads were removed from an IL6-knockout mouse (donor) and stitched to 
the mesenterium of a wildtype mouse (recipient; pTx-IL6KO). (A) Intraperitoneal glucose 
tolerance test (2 g glucose/kg body weight) was performed four weeks after surgical 
procedure in mice receiving portal transplants (pTx-IL6KO; ◊) or in sham-operated mice (?). 
(B) Insulin (1U/kg) was injected i.p. in overnight fasted mice 5 weeks after transplantation. 
Liver and muscle samples were harvested 15 minutes later and phosphorylation of Akt at 
S473 was determined by Western blotting. A representative blot is shown in the upper panel. 
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Results are the mean ± SEM of 3 animals. (C) Five weeks after transplantation liver tissue 
was collected and rtPCR was performed. Results are the mean ± SEM of 2-3 animals.  
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Tab. 1 
Metabolic Characteristics of sham-operated and portal transplanted mice 
 
 Sham pTx 
Before transplantation   
Body weight (g) 22.3 ± 0.7 23.0 ± 0.4 
Fat pad weight (mg):   
- Transplant  150 ± 7 
   
At sacrifice   
Body weight (g) 25.2 ± 0.4 26.0 ± 0.5 
Fat pad weight (mg):   
- Transplant  117 ± 12 
- Epididymidal 215 ± 22 222 ± 29 
- Mesenteric 135 ± 12 138 ± 11 
- Retroperitoneal 68 ± 11 59 ± 10 
- Inguinal 193 ± 21 188 ± 16 
Glucose (mM) 5.6 ± 0.7 5.7 ± 0.2 
Insulin (pg/ml) 1295 ± 486 1479 ± 338 
Adiponectin (μg/ml) 27.5 ± 3.7 33.0 ± 4.5 
Leptin (pg/ml) 66.9 ± 14.6 81.6 ± 23.7 
IL-6 (pg/ml) 6.5 ± 0.9 6.8 ± 1.6 
FFA (mM) 0.31 ± 0.04 0.39 ± 0.08 
 
Results are the means ± SEM of five to ten animals. Blood samples were taken 4 hours after 
fasting. 
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